What is Definitive Healthcare's operating income?

Definitive Healthcare's total operating income in 2025 was -$224.27 million, based on the following breakdown: Total Gross Profit: $183.28 million Total Operating Expenses: $407.55 million

Definitive Healthcare (DH) Financials

$0.84 +0.03 (+4.24%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$0.83 0.00 (-0.32%)

As of 07/10/2026 04:10 PM Eastern

Compare

Annual Income Statements for Definitive Healthcare

This table shows Definitive Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	0.00	-18	-7.22	-202	-413	-139
Consolidated Net Income / (Loss)	0.00	-62	-24	-290	-591	-199
Net Income / (Loss) Continuing Operations	-53	-62	-24	-290	-591	-199
Total Pre-Tax Income	-53	-63	-42	-308	-634	-209
Total Operating Income	-16	-27	-44	-330	-711	-224
Total Gross Profit	88	125	180	204	197	183
Total Revenue	118	166	223	251	252	242
Operating Revenue	118	166	223	251	252	242
Total Cost of Revenue	30	41	43	47	55	58
Operating Cost of Revenue	30	41	43	47	55	58
Total Operating Expenses	104	153	224	534	908	408
Selling, General & Admin Expense	14	33	52	59	49	52
Marketing Expense	34	56	90	95	84	82
Research & Development Expense	11	19	35	42	37	35
Depreciation Expense	40	39	40	39	38	36
Impairment Charge	-	0.00	0.00	287	689	196
Restructuring Charge	3.78	6.29	7.89	11	12	7.62
Total Other Income / (Expense), net	-37	-35	2.17	22	77	15
Interest Expense	36	36	11	15	15	12
Interest & Investment Income	-	0.03	2.79	14	15	6.95
Other Income / (Expense), net	-0.22	0.29	11	23	77	20
Income Tax Expense	0.00	-0.44	-18	-19	-42	-9.96
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-44	-17	-87	-178	-60
Basic Earnings per Share	$0.00	($0.19)	($0.07)	($1.79)	($3.54)	($1.30)
Weighted Average Basic Shares Outstanding	0.00	91.92M	101.11M	112.76M	116.64M	106.65M
Diluted Earnings per Share	$0.00	($0.19)	($0.07)	($1.79)	($3.54)	($1.30)
Weighted Average Diluted Shares Outstanding	0.00	91.92M	101.11M	112.76M	116.64M	106.65M
Weighted Average Basic & Diluted Shares Outstanding	0.00	91.92M	107.60M	117.72M	112.91M	104.47M

This table shows Definitive Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-172	-10	-9.52	-214	-131	-59	-107	-7.55	-15	-9.32	-139
Consolidated Net Income / (Loss)	-249	-13	-13	-306	-188	-85	-155	-9.27	-18	-17	-192
Net Income / (Loss) Continuing Operations	-249	-13	-13	-306	-188	-85	-155	-9.27	-18	-17	-192
Total Pre-Tax Income	-266	-12	-13	-328	-202	-91	-166	-8.81	-17	-17	-196
Total Operating Income	-295	-10	-16	-370	-225	-100	-185	-4.17	-8.69	-27	-201
Total Gross Profit	53	53	50	50	49	48	44	47	46	47	42
Total Revenue	65	66	63	64	63	62	59	61	60	62	56
Operating Revenue	65	66	63	64	63	62	59	61	60	62	56
Total Cost of Revenue	12	13	13	13	14	15	15	14	14	15	14
Operating Cost of Revenue	12	13	13	13	14	15	15	14	14	15	14
Total Operating Expenses	349	63	67	420	274	147	229	51	55	74	243
Selling, General & Admin Expense	15	17	17	13	11	8.50	12	13	12	14	12
Marketing Expense	23	24	22	22	20	20	21	20	20	20	20
Research & Development Expense	11	12	10	10	7.28	8.98	9.30	7.97	7.55	9.95	6.50
Depreciation Expense	9.80	9.94	9.32	9.41	9.47	9.41	8.53	9.00	9.08	9.21	8.33
Impairment Charge	287	-	0.00	364	228	-	177	0.00	0.00	20	197
Restructuring Charge	3.51	1.82	8.53	2.85	-2.00	2.84	1.27	0.67	5.31	0.38	-0.77
Total Other Income / (Expense), net	29	-2.11	2.75	42	24	8.95	19	-4.64	-8.58	9.43	5.50
Interest Expense	3.90	3.90	3.82	3.76	3.75	3.51	2.94	2.99	3.00	2.87	2.63
Interest & Investment Income	3.46	3.77	3.93	3.72	3.74	3.21	2.05	1.75	1.67	1.48	1.30
Other Income / (Expense), net	30	-1.98	2.64	42	24	9.25	20	-3.40	-7.25	11	6.83
Income Tax Expense	-18	1.18	-0.78	-22	-14	-5.90	-11	0.46	0.52	-0.05	-3.44
Net Income / (Loss) Attributable to Noncontrolling Interest	-77	-3.13	-3.20	-93	-57	-26	-48	-1.71	-2.95	-7.83	-54
Basic Earnings per Share	($1.50)	($0.10)	($0.08)	($1.81)	($1.12)	($0.53)	($0.95)	($0.07)	($0.14)	($0.14)	($1.32)
Weighted Average Basic Shares Outstanding	114.53M	112.76M	117.43M	117.75M	116.38M	116.64M	112.78M	106.82M	103.78M	106.65M	104.68M
Diluted Earnings per Share	($1.50)	($0.10)	($0.08)	($1.81)	($1.12)	($0.53)	($0.95)	($0.07)	($0.14)	($0.14)	($1.32)
Weighted Average Diluted Shares Outstanding	114.53M	112.76M	117.43M	117.75M	116.38M	116.64M	112.78M	106.82M	103.78M	106.65M	104.68M
Weighted Average Basic & Diluted Shares Outstanding	116.33M	117.72M	117.93M	117.12M	115.52M	112.91M	107.34M	104.09M	103.30M	104.47M	105.52M

This table details how cash moves in and out of Definitive Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	13	363	-240	-24	-25	57
Net Cash From Operating Activities	23	25	36	41	58	54
Net Cash From Continuing Operating Activities	21	25	35	33	58	54
Net Income / (Loss) Continuing Operations	-53	-62	-24	-290	-591	-199
Consolidated Net Income / (Loss)	-53	-62	-24	-290	-591	-199
Depreciation Expense	1.15	1.75	2.19	1.95	2.25	3.30
Amortization Expense	62	65	64	63	66	69
Non-Cash Adjustments To Reconcile Net Income	13	24	15	315	638	188
Changes in Operating Assets and Liabilities, net	-2.75	-2.95	-23	-57	-56	-6.94
Net Cash From Investing Activities	-24	-47	-249	-32	-26	154
Net Cash From Continuing Investing Activities	-24	-47	-249	-32	-26	154
Purchase of Property, Plant & Equipment	-1.40	-6.73	-8.33	-2.98	-12	-17
Acquisitions	-22	-40	-56	-45	-14	0.00
Purchase of Investments	0.00	0.00	-338	-259	-304	-64
Sale and/or Maturity of Investments	0.00	0.00	154	275	304	235
Net Cash From Financing Activities	17	384	-27	-26	-57	-151
Net Cash From Continuing Financing Activities	17	384	-27	-26	-57	-151
Repayment of Debt	-30	-478	-6.88	-8.59	-14	-254
Repurchase of Common Equity	0.00	-243	0.00	-0.03	-22	-49
Payment of Dividends	-2.94	-8.13	-13	-12	-5.14	-3.15
Issuance of Debt	25	275	-	0.00	0.00	175
Issuance of Common Equity	0.00	835	-1.73	-	0.00	0.00
Other Financing Activities, net	24	4.00	-5.22	-4.68	-15	-19
Cash Interest Paid	26	30	10	14	14	11
Cash Income Taxes Paid	0.00	0.01	0.00	0.14	0.00	0.83

This table details how cash moves in and out of Definitive Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-55	45	-25	15	16	-32	-0.10	-26	27	55	-5.53
Net Cash From Operating Activities	9.49	4.71	17	14	19	8.14	26	9.30	16	2.72	12
Net Cash From Continuing Operating Activities	1.69	4.71	17	14	19	8.14	26	9.50	16	2.72	12
Net Income / (Loss) Continuing Operations	-249	-13	-13	-306	-188	-85	-155	-9.27	-18	-17	-192
Consolidated Net Income / (Loss)	-249	-13	-13	-306	-188	-85	-155	-9.27	-18	-17	-192
Depreciation Expense	0.43	0.56	0.55	0.60	0.56	0.53	0.59	0.87	0.85	0.99	1.00
Amortization Expense	16	16	16	16	17	17	17	18	17	17	16
Non-Cash Adjustments To Reconcile Net Income	266	29	11	329	205	93	159	7.43	7.74	13	196
Changes in Operating Assets and Liabilities, net	-32	-27	1.66	-26	-15	-17	4.01	-7.12	7.55	-11	-8.94
Net Cash From Investing Activities	-54	54	-24	15	8.96	-26	84	-10	24	56	-6.22
Net Cash From Continuing Investing Activities	-54	54	-24	15	8.96	-26	84	-10	24	56	-6.22
Purchase of Property, Plant & Equipment	-0.31	-0.59	-0.27	-0.41	-0.77	-11	-7.71	-2.29	-2.28	-4.44	-3.20
Purchase of Investments	-81	-46	-84	-40	-69	-112	-12	-52	-	-	-13
Sale and/or Maturity of Investments	72	101	74	55	78	96	103	44	26	61	9.48
Net Cash From Financing Activities	-10	-6.06	-17	-14	-12	-13	-110	-25	-12	-3.91	-11
Net Cash From Continuing Financing Activities	-10	-6.06	-17	-14	-12	-13	-110	-25	-12	-3.91	-11
Repayment of Debt	-1.72	-3.44	-3.44	-3.44	-3.44	-3.44	-248	-2.19	-2.19	-2.19	-2.19
Repurchase of Common Equity	-	-0.03	0.00	-	-8.03	-7.33	-21	-19	-9.22	-	0.00
Issuance of Debt	-	-	0.00	-	-	-	175	-	-	-	0.00
Other Financing Activities, net	-0.78	-1.04	-14	-0.97	-0.50	-0.28	-16	-0.61	-1.06	-1.40	-8.69
Cash Interest Paid	3.68	3.68	3.64	3.59	3.65	-11	2.24	2.96	2.87	2.73	2.47
Cash Income Taxes Paid	-	-	0.00	-	-	-	0.03	-	0.18	0.63	0.09

This table presents Definitive Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1,745	2,118	2,123	1,826	1,089	735
Total Current Assets	64	444	414	394	370	258
Cash & Equivalents	25	387	147	131	105	164
Short-Term Investments	-	0.00	185	177	185	17
Accounts Receivable	33	43	59	59	53	52
Prepaid Expenses	3.02	6.52	13	13	13	12
Other Current Assets	2.95	6.88	10	13	14	13
Plant, Property, & Equipment, net	3.25	5.07	4.46	4.47	3.79	13
Total Noncurrent Assets	1,672	1,668	1,704	1,428	715	465
Goodwill	1,261	1,263	1,325	1,075	393	197
Intangible Assets	410	352	351	323	298	247
Other Noncurrent Operating Assets	0.47	20	29	29	24	21
Total Liabilities & Shareholders' Equity	1,745	2,118	2,123	1,826	1,089	735
Total Liabilities	550	618	641	627	482	357
Total Current Liabilities	89	123	141	171	161	157
Short-Term Debt	4.68	6.88	8.59	14	14	8.75
Accounts Payable	5.66	4.65	3.95	5.79	11	3.60
Accrued Expenses	17	28	27	52	41	45
Current Deferred Revenue	61	84	100	97	93	97
Other Current Liabilities	-	0.00	1.52	2.24	2.41	2.68
Total Noncurrent Liabilities	461	495	500	456	321	200
Long-Term Debt	457	264	256	243	229	156
Noncurrent Deferred Revenue	0.14	0.41	0.24	0.01	0.03	2.38
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	229	231	194	25	34
Other Noncurrent Operating Liabilities	3.74	1.29	13	19	67	7.40
Total Equity & Noncontrolling Interests	1,196	1,500	1,482	1,199	607	379
Total Preferred & Common Equity	-0.13	871	949	861	444	281
Total Common Equity	-0.13	871	949	861	444	281
Common Stock	0.00	889	970	1,087	1,086	1,062
Retained Earnings	0.00	-18	-25	-227	-641	-780
Accumulated Other Comprehensive Income / (Loss)	-0.13	0.06	3.67	2.11	-0.61	-1.45
Noncontrolling Interest	1,196	629	533	338	163	98

This table presents Definitive Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	2,117	2,105	1,820	1,810	1,422	1,182	809	770	756	515
Total Current Assets	421	421	375	379	368	369	273	249	246	246
Cash & Equivalents	125	132	77	106	121	138	106	81	108	158
Short-Term Investments	219	219	230	189	176	168	95	103	78	20
Accounts Receivable	52	45	41	57	44	36	43	38	34	39
Prepaid Expenses	15	14	15	13	14	14	16	14	13	16
Other Current Assets	11	12	12	14	14	13	14	13	13	12
Plant, Property, & Equipment, net	4.45	4.49	4.63	4.10	3.53	3.70	9.48	11	12	14
Total Noncurrent Assets	1,691	1,679	1,440	1,427	1,051	809	526	510	498	255
Goodwill	1,325	1,325	1,074	1,082	718	490	217	217	217	0.00
Intangible Assets	338	326	336	318	307	295	285	271	260	235
Other Noncurrent Operating Assets	28	29	29	27	25	24	24	22	21	20
Total Liabilities & Shareholders' Equity	2,117	2,105	1,820	1,810	1,422	1,182	809	770	756	515
Total Liabilities	653	649	616	615	536	486	373	359	366	324
Total Current Liabilities	151	148	147	165	153	148	156	151	154	140
Short-Term Debt	10	12	14	14	14	14	8.75	8.75	8.75	8.75
Accounts Payable	4.54	3.65	5.57	4.90	6.08	9.96	8.22	7.90	8.57	6.02
Accrued Expenses	29	33	36	36	34	36	27	31	42	24
Current Deferred Revenue	105	97	90	108	97	86	110	101	92	99
Other Current Liabilities	1.64	1.71	2.13	2.31	2.36	2.50	2.42	2.46	2.66	2.66
Total Noncurrent Liabilities	502	501	469	450	383	338	217	208	212	184
Long-Term Debt	252	249	246	239	236	233	162	160	158	154
Noncurrent Deferred Revenue	0.14	0.15	0.07	0.01	0.00	0.02	2.79	0.57	0.04	0.12
Noncurrent Deferred & Payable Income Tax Liabilities	239	242	204	192	128	90	37	37	15	23
Other Noncurrent Operating Liabilities	11	10	19	19	19	15	14	9.91	39	6.07
Total Equity & Noncontrolling Interests	1,464	1,455	1,203	1,195	886	696	436	411	390	191
Total Preferred & Common Equity	984	1,008	863	860	645	507	323	304	285	146
Total Common Equity	984	1,008	863	860	645	507	323	304	285	146
Common Stock	1,019	1,051	1,077	1,096	1,094	1,088	1,072	1,060	1,057	1,066
Retained Earnings	-37	-46	-217	-237	-451	-581	-748	-755	-770	-918
Accumulated Other Comprehensive Income / (Loss)	2.79	3.25	3.05	1.66	1.06	0.34	-1.26	-1.34	-1.54	-1.56
Noncontrolling Interest	479	447	340	335	242	189	113	108	105	44

This table displays calculated financial ratios and metrics derived from Definitive Healthcare's official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	88,263,333.00	105,080,062.00	-	-	103,303,387.00
DEI Adjusted Shares Outstanding	0.00	88,263,333.00	105,080,062.00	-	-	103,303,387.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-0.20	-0.07	-	-	-1.34
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	40.43%	34.00%	12.92%	0.31%	-4.24%
EBITDA Growth	0.00%	-16.50%	-16.38%	-831.86%	-134.53%	76.68%
EBIT Growth	0.00%	-67.76%	-23.84%	-816.27%	-106.61%	67.73%
NOPAT Growth	0.00%	-71.96%	-61.23%	-648.81%	-115.53%	68.45%
Net Income Growth	0.00%	0.00%	61.20%	-1,097.85%	-104.21%	66.30%
EPS Growth	0.00%	0.00%	63.16%	-2,457.14%	-97.77%	63.28%
Operating Cash Flow Growth	0.00%	8.59%	41.12%	15.77%	41.29%	-7.59%
Free Cash Flow Firm Growth	0.00%	0.00%	-136.90%	138.08%	148.15%	-55.16%
Invested Capital Growth	0.00%	-16.99%	4.75%	-18.88%	-51.18%	-35.21%
Revenue Q/Q Growth	0.00%	0.00%	6.86%	2.17%	-1.42%	-0.31%
EBITDA Q/Q Growth	0.00%	0.00%	10.30%	-0.47%	-15.90%	36.30%
EBIT Q/Q Growth	0.00%	0.00%	12.28%	-0.78%	-14.09%	26.71%
NOPAT Q/Q Growth	0.00%	0.00%	8.27%	0.14%	-14.40%	24.54%
Net Income Q/Q Growth	0.00%	0.00%	47.32%	-7.12%	-13.72%	25.32%
EPS Q/Q Growth	0.00%	0.00%	75.00%	-13.29%	-13.83%	23.08%
Operating Cash Flow Q/Q Growth	0.00%	-15.01%	-19.17%	27.68%	6.26%	-9.15%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	446.53%	6.14%	-30.49%
Invested Capital Q/Q Growth	0.00%	0.00%	1.48%	-0.75%	-12.01%	-2.09%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	74.25%	75.51%	80.86%	81.11%	78.30%	75.88%
EBITDA Margin	39.90%	23.72%	14.80%	-95.94%	-224.30%	-54.62%
Operating Margin	-13.43%	-16.44%	-19.78%	-131.18%	-281.85%	-92.86%
EBIT Margin	-13.61%	-16.26%	-15.03%	-121.96%	-251.19%	-84.64%
Profit (Net Income) Margin	0.00%	-37.51%	-10.86%	-115.20%	-234.51%	-82.52%
Tax Burden Percent	0.00%	99.29%	57.74%	93.98%	93.33%	95.24%
Interest Burden Percent	326.53%	232.27%	125.14%	100.51%	100.04%	102.37%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-0.68%	-1.28%	-2.23%	-18.02%	-58.28%	-34.01%
ROIC Less NNEP Spread (ROIC-NNEP)	1.90%	-31.96%	-8.36%	80.53%	131.75%	100.08%
Return on Net Nonoperating Assets (RNNOA)	0.68%	-3.34%	0.61%	-3.58%	-7.21%	-6.40%
Return on Equity (ROE)	0.00%	-4.62%	-1.62%	-21.60%	-65.48%	-40.42%
Cash Return on Invested Capital (CROIC)	0.00%	17.28%	-6.87%	2.82%	10.51%	8.71%
Operating Return on Assets (OROA)	-0.92%	-1.40%	-1.58%	-15.53%	-43.46%	-22.40%
Return on Assets (ROA)	0.00%	-3.23%	-1.14%	-14.67%	-40.58%	-21.84%
Return on Common Equity (ROCE)	0.00%	-1.49%	-0.99%	-14.59%	-47.34%	-29.73%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-7.15%	-2.55%	-33.62%	-133.10%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-19	-31	-231	-498	-157
NOPAT Margin	-9.40%	-11.51%	-13.85%	-91.82%	-197.29%	-65.00%
Net Nonoperating Expense Percent (NNEP)	-2.58%	30.68%	6.13%	-98.55%	-190.03%	-134.10%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-1.77%	-15.86%	-58.52%	-28.87%
Cost of Revenue to Revenue	25.75%	24.49%	19.14%	18.89%	21.70%	24.12%
SG&A Expenses to Revenue	12.14%	19.78%	23.16%	23.41%	19.53%	21.38%
R&D to Revenue	9.35%	11.17%	15.67%	16.88%	14.48%	14.40%
Operating Expenses to Revenue	87.68%	91.95%	100.64%	212.29%	360.14%	168.74%
Earnings before Interest and Taxes (EBIT)	-16	-27	-33	-307	-634	-204
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	47	39	33	-241	-566	-132
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.77	1.22	1.34	1.07	1.05
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.55	14.52	5.19	4.60	1.88	1.23
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.26	2.14	1.15	1.26	1.05	1.04
Enterprise Value to Revenue (EV/Rev)	17.35	17.40	7.28	5.74	2.34	1.57
Enterprise Value to EBITDA (EV/EBITDA)	43.49	73.35	49.16	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	88.42	114.68	45.54	35.02	10.15	7.03
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	11.24	0.00	39.90	6.58	9.41
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.39	0.18	0.18	0.21	0.40	0.43
Long-Term Debt to Equity	0.38	0.18	0.17	0.20	0.38	0.41
Financial Leverage	0.36	0.10	-0.07	-0.04	-0.05	-0.06
Leverage Ratio	1.46	1.43	1.42	1.47	1.61	1.85
Compound Leverage Factor	4.77	3.33	1.78	1.48	1.61	1.89
Debt to Total Capital	27.87%	15.29%	15.14%	17.61%	28.59%	30.31%
Short-Term Debt to Total Capital	0.28%	0.39%	0.49%	0.94%	1.62%	1.61%
Long-Term Debt to Total Capital	27.58%	14.90%	14.65%	16.67%	26.97%	28.70%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	72.14%	35.50%	30.52%	23.21%	19.15%	18.00%
Common Equity to Total Capital	-0.01%	49.21%	54.34%	59.18%	52.26%	51.69%
Debt to EBITDA	9.78	6.87	8.02	-1.06	-0.43	-1.25
Net Debt to EBITDA	9.26	-3.79	-2.05	0.21	0.08	0.12
Long-Term Debt to EBITDA	9.69	6.69	7.76	-1.01	-0.41	-1.18
Debt to NOPAT	-41.54	-14.16	-8.57	-1.11	-0.49	-1.05
Net Debt to NOPAT	-39.31	7.82	2.19	0.22	0.09	0.10
Long-Term Debt to NOPAT	-41.11	-13.80	-8.30	-1.05	-0.46	-0.99
Altman Z-Score	0.48	2.55	1.27	0.66	-1.69	-1.41
Noncontrolling Interest Sharing Ratio	100.01%	67.68%	38.96%	32.48%	27.72%	26.44%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.72	3.61	2.94	2.31	2.30	1.64
Quick Ratio	0.65	3.50	2.78	2.15	2.13	1.49
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	257	-95	36	90	40
Operating Cash Flow to CapEx	1,664.30%	374.57%	427.32%	1,383.61%	471.45%	321.63%
Free Cash Flow to Firm to Interest Expense	0.00	7.19	-8.47	2.38	6.05	3.41
Operating Cash Flow to Interest Expense	0.64	0.70	3.18	2.71	3.92	4.56
Operating Cash Flow Less CapEx to Interest Expense	0.60	0.52	2.43	2.51	3.09	3.14
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.07	0.09	0.11	0.13	0.17	0.26
Accounts Receivable Turnover	3.57	4.35	4.36	4.26	4.48	4.59
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	36.43	39.96	46.71	56.28	61.05	29.33
Accounts Payable Turnover	5.38	7.89	9.91	9.75	6.61	8.11
Days Sales Outstanding (DSO)	102.14	83.96	83.72	85.69	81.39	79.50
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	67.83	46.26	36.82	37.42	55.18	44.99
Cash Conversion Cycle (CCC)	34.31	37.71	46.90	48.27	26.21	34.51
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	1,627	1,350	1,414	1,147	560	363
Invested Capital Turnover	0.07	0.11	0.16	0.20	0.30	0.52
Increase / (Decrease) in Invested Capital	0.00	-276	64	-267	-587	-197
Enterprise Value (EV)	2,053	2,891	1,620	1,442	591	378
Market Capitalization	420	2,412	1,155	1,156	475	296
Book Value per Share	($0.01)	$9.87	$9.03	$7.40	$3.85	$2.72
Tangible Book Value per Share	($107.47)	($8.43)	($6.91)	($4.61)	($2.14)	($1.58)
Total Capital	1,657	1,771	1,746	1,455	850	544
Total Debt	462	271	264	256	243	165
Total Long-Term Debt	457	264	256	243	229	156
Net Debt	437	-149	-68	-52	-47	-16
Capital Expenditures (CapEx)	1.40	6.73	8.33	2.98	12	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-45	-60	-50	-71	-67	-71
Debt-free Net Working Capital (DFNWC)	-20	328	282	237	223	110
Net Working Capital (NWC)	-25	321	273	223	209	101
Net Nonoperating Expense (NNE)	-11	43	-6.65	59	94	42
Net Nonoperating Obligations (NNO)	431	-149	-68	-52	-47	-16
Total Depreciation and Amortization (D&A)	63	66	66	65	68	73
Debt-free, Cash-free Net Working Capital to Revenue	-38.01%	-35.82%	-22.52%	-28.27%	-26.73%	-29.53%
Debt-free Net Working Capital to Revenue	-17.07%	197.40%	126.53%	94.26%	88.33%	45.37%
Net Working Capital to Revenue	-21.03%	193.26%	122.67%	88.80%	82.87%	41.74%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.19)	($0.06)	($1.79)	($3.54)	($1.30)
Adjusted Weighted Average Basic Shares Outstanding	0.00	97.39M	101.11M	112.76M	116.64M	106.65M
Adjusted Diluted Earnings per Share	$0.00	($0.19)	($0.06)	($1.79)	($3.54)	($1.30)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	97.39M	101.11M	112.76M	116.64M	106.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.19)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	91.92M	107.60M	117.72M	112.91M	104.47M
Normalized Net Operating Profit after Tax (NOPAT)	-8.48	-15	-25	-22	-6.82	-14
Normalized NOPAT Margin	-7.16%	-8.86%	-11.37%	-8.61%	-2.70%	-5.97%
Pre Tax Income Margin	-44.46%	-37.78%	-18.81%	-122.58%	-251.28%	-86.64%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-0.44	-0.76	-2.99	-20.17	-42.70	-17.33
NOPAT to Interest Expense	-0.30	-0.53	-2.75	-15.19	-33.54	-13.31
EBIT Less CapEx to Interest Expense	-0.48	-0.94	-3.73	-20.36	-43.53	-18.75
NOPAT Less CapEx to Interest Expense	-0.34	-0.72	-3.50	-15.38	-34.37	-14.73
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	-13.04%	-53.23%	-4.24%	-0.87%	-1.58%
Augmented Payout Ratio	0.00%	-403.71%	-53.23%	-4.25%	-4.65%	-26.39%

This table displays calculated financial ratios and metrics derived from Definitive Healthcare's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	112,911,325.00	107,341,903.00	104,086,210.00	103,303,387.00	104,472,371.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	112,911,325.00	107,341,903.00	104,086,210.00	103,303,387.00	104,472,371.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.95	-0.07	-0.14	-0.09	-1.33
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.84%	8.80%	7.23%	4.56%	-4.02%	-5.53%	-6.76%	-4.69%	-4.23%	-1.21%	-5.51%
EBITDA Growth	-2,321.10%	-19.67%	3,673.08%	-9,662.21%	26.00%	-1,686.79%	-5,101.73%	103.50%	101.22%	102.96%	-20.45%
EBIT Growth	-5,894.34%	-24.68%	14.42%	-2,449.28%	24.17%	-648.71%	-1,113.10%	97.69%	92.09%	82.49%	-17.79%
NOPAT Growth	-2,835.58%	4.34%	-32.42%	-2,962.22%	23.70%	-887.73%	-1,037.21%	98.87%	96.15%	73.26%	-8.93%
Net Income Growth	-3,512.03%	-326.97%	20.37%	-2,538.41%	24.47%	-534.01%	-1,119.48%	96.97%	90.53%	79.76%	-24.02%
EPS Growth	-4,900.00%	-190.91%	27.27%	-2,162.50%	25.33%	-430.00%	-1,087.50%	96.13%	87.50%	73.58%	-38.95%
Operating Cash Flow Growth	-11.21%	211.59%	10.91%	16.64%	104.83%	72.75%	57.13%	-33.73%	-19.27%	-66.56%	-55.64%
Free Cash Flow Firm Growth	187.94%	463.77%	502.93%	65.73%	1,065.65%	99.11%	182.50%	64.67%	-28.16%	-65.50%	-85.40%
Invested Capital Growth	-17.06%	-18.88%	-16.62%	-38.53%	-44.93%	-51.18%	-64.75%	-52.82%	-41.77%	-35.21%	-56.85%
Revenue Q/Q Growth	7.17%	0.93%	-3.72%	0.40%	-1.63%	-0.65%	-4.97%	2.63%	-1.16%	2.48%	-9.11%
EBITDA Q/Q Growth	-7,754.10%	101.85%	-36.05%	-10,675.94%	40.77%	60.39%	-101.58%	107.39%	-79.32%	-4.09%	-8,316.36%
EBIT Q/Q Growth	-1,965.50%	95.46%	-12.83%	-2,310.47%	38.56%	55.19%	-82.81%	95.42%	-110.58%	0.76%	-1,129.50%
NOPAT Q/Q Growth	-2,347.01%	96.59%	-61.20%	-2,174.85%	39.03%	55.82%	-85.60%	97.74%	-108.35%	-206.48%	-655.96%
Net Income Q/Q Growth	-2,042.94%	94.63%	4.82%	-2,307.51%	38.66%	54.90%	-83.07%	94.03%	-92.03%	3.63%	-1,021.79%
EPS Q/Q Growth	-1,775.00%	93.33%	20.00%	-2,162.50%	38.12%	52.68%	-79.25%	92.63%	-100.00%	0.00%	-842.86%
Operating Cash Flow Q/Q Growth	-21.18%	-50.36%	252.28%	-15.37%	38.40%	-58.14%	220.42%	-64.31%	68.60%	-82.66%	325.15%
Free Cash Flow Firm Q/Q Growth	-80.78%	737.76%	-15.96%	22.45%	35.21%	43.10%	19.24%	-28.62%	-41.02%	-31.27%	-49.53%
Invested Capital Q/Q Growth	-15.36%	-0.75%	0.48%	-27.18%	-24.17%	-12.01%	-27.45%	-2.53%	-6.41%	-2.09%	-51.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.79%	81.02%	79.37%	79.16%	78.20%	76.42%	73.93%	76.73%	76.60%	76.23%	74.47%
EBITDA Margin	-381.39%	6.98%	4.64%	-488.33%	-294.05%	-117.24%	-248.69%	17.91%	3.75%	3.51%	-317.03%
Operating Margin	-452.17%	-15.29%	-25.60%	-579.95%	-359.45%	-159.84%	-312.19%	-6.86%	-14.47%	-43.27%	-359.90%
EBIT Margin	-406.87%	-18.29%	-21.44%	-514.68%	-321.45%	-144.99%	-278.91%	-12.46%	-26.54%	-25.70%	-347.69%
Profit (Net Income) Margin	-380.69%	-20.27%	-20.03%	-480.39%	-299.57%	-136.01%	-262.02%	-15.25%	-29.63%	-27.87%	-343.93%
Tax Burden Percent	93.41%	109.64%	94.22%	93.32%	93.19%	93.49%	93.44%	105.18%	103.03%	99.69%	98.25%
Interest Burden Percent	100.16%	101.04%	99.18%	100.01%	100.00%	100.34%	100.54%	116.40%	108.35%	108.75%	100.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-61.09%	-2.10%	-3.61%	-95.16%	-71.82%	-33.05%	-69.49%	-1.91%	-4.87%	-15.85%	-206.38%
ROIC Less NNEP Spread (ROIC-NNEP)	2.87%	8.47%	-1.43%	-25.66%	-15.29%	-2.64%	2.33%	18.58%	25.17%	-20.58%	22.81%
Return on Net Nonoperating Assets (RNNOA)	-0.14%	-0.38%	0.07%	1.50%	0.86%	0.14%	-0.10%	-0.89%	-1.81%	1.32%	-1.63%
Return on Equity (ROE)	-61.23%	-2.48%	-3.55%	-93.67%	-70.97%	-32.91%	-69.59%	-2.79%	-6.68%	-14.53%	-208.01%
Cash Return on Invested Capital (CROIC)	0.52%	2.82%	-0.30%	3.84%	9.43%	10.51%	16.80%	13.55%	11.49%	8.71%	21.48%
Operating Return on Assets (OROA)	-50.83%	-2.33%	-2.79%	-75.43%	-54.81%	-25.09%	-52.81%	-2.78%	-6.64%	-6.80%	-125.19%
Return on Assets (ROA)	-47.56%	-2.58%	-2.61%	-70.40%	-51.08%	-23.53%	-49.61%	-3.41%	-7.41%	-7.38%	-123.84%
Return on Common Equity (ROCE)	-41.02%	-1.67%	-2.46%	-66.13%	-51.19%	-23.79%	-50.48%	-2.04%	-4.87%	-10.69%	-155.69%
Return on Equity Simple (ROE_SIMPLE)	-31.32%	0.00%	-33.29%	-90.10%	-102.68%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-207	-7.06	-11	-259	-158	-70	-129	-2.92	-6.08	-19	-141
NOPAT Margin	-316.52%	-10.70%	-17.92%	-405.96%	-251.62%	-111.89%	-218.53%	-4.80%	-10.13%	-30.29%	-251.93%
Net Nonoperating Expense Percent (NNEP)	-63.96%	-10.57%	-2.18%	-69.51%	-56.53%	-30.41%	-71.82%	-20.48%	-30.04%	4.73%	-229.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.48%	-	-	-	-8.20%	-21.31%	-0.50%	-1.09%	-3.43%	-39.87%
Cost of Revenue to Revenue	18.21%	18.98%	20.63%	20.84%	21.80%	23.58%	26.07%	23.27%	23.40%	23.77%	25.53%
SG&A Expenses to Revenue	22.27%	25.13%	26.60%	19.65%	18.11%	13.65%	20.73%	20.86%	20.59%	23.27%	21.61%
R&D to Revenue	16.47%	17.55%	15.96%	15.88%	11.61%	14.42%	15.71%	13.12%	12.58%	16.18%	11.62%
Operating Expenses to Revenue	533.96%	96.31%	104.96%	659.11%	437.66%	236.27%	386.12%	83.59%	91.07%	119.50%	434.37%
Earnings before Interest and Taxes (EBIT)	-266	-12	-14	-328	-202	-90	-165	-7.57	-16	-16	-194
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-249	4.60	2.94	-311	-184	-73	-147	11	2.25	2.16	-177
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.05	1.34	1.10	1.00	1.03	1.07	1.01	1.38	1.48	1.05	0.88
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.68	4.60	3.72	2.49	2.05	1.88	1.32	1.71	1.74	1.23	0.54
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.04	1.26	1.08	1.00	1.03	1.05	1.01	1.29	1.37	1.04	0.90
Enterprise Value to Revenue (EV/Rev)	4.87	5.74	4.86	3.24	2.55	2.34	1.65	2.09	2.10	1.57	0.66
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	37.14	35.02	29.02	18.71	11.93	10.15	6.06	8.12	8.59	7.03	4.01
Enterprise Value to Free Cash Flow (EV/FCFF)	181.13	39.90	0.00	19.82	7.73	6.58	3.13	6.11	8.79	9.41	2.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.21	0.21	0.28	0.35	0.40	0.39	0.41	0.43	0.43	0.85
Long-Term Debt to Equity	0.20	0.20	0.20	0.27	0.33	0.38	0.37	0.39	0.41	0.41	0.81
Financial Leverage	-0.05	-0.04	-0.05	-0.06	-0.06	-0.05	-0.04	-0.05	-0.07	-0.06	-0.07
Leverage Ratio	1.47	1.47	1.48	1.51	1.58	1.61	1.61	1.69	1.79	1.85	2.11
Compound Leverage Factor	1.47	1.49	1.46	1.51	1.58	1.62	1.61	1.97	1.93	2.01	2.13
Debt to Total Capital	17.74%	17.61%	17.47%	21.98%	26.16%	28.59%	28.19%	29.13%	29.99%	30.31%	46.04%
Short-Term Debt to Total Capital	0.94%	0.94%	0.95%	1.21%	1.46%	1.62%	1.44%	1.51%	1.57%	1.61%	2.48%
Long-Term Debt to Total Capital	16.80%	16.67%	16.52%	20.77%	24.70%	26.97%	26.75%	27.62%	28.42%	28.70%	43.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	23.25%	23.21%	23.12%	21.26%	20.07%	19.15%	18.64%	18.55%	18.83%	18.00%	12.58%
Common Equity to Total Capital	59.01%	59.18%	59.41%	56.76%	53.77%	52.26%	53.17%	52.32%	51.18%	51.69%	41.38%
Debt to EBITDA	-1.08	-1.06	-1.06	-0.45	-0.50	-0.43	-0.24	-0.43	-0.81	-1.25	-1.00
Net Debt to EBITDA	0.20	0.21	0.18	0.08	0.12	0.08	0.04	0.04	0.09	0.12	0.09
Long-Term Debt to EBITDA	-1.02	-1.01	-1.00	-0.43	-0.48	-0.41	-0.23	-0.41	-0.76	-1.18	-0.95
Debt to NOPAT	-1.12	-1.11	-1.08	-0.52	-0.57	-0.49	-0.28	-0.47	-0.80	-1.05	-0.97
Net Debt to NOPAT	0.21	0.22	0.18	0.10	0.14	0.09	0.05	0.04	0.09	0.10	0.09
Long-Term Debt to NOPAT	-1.06	-1.05	-1.02	-0.49	-0.53	-0.46	-0.26	-0.45	-0.76	-0.99	-0.91
Altman Z-Score	0.52	1.20	1.00	-0.12	-0.17	-0.04	-0.96	-0.24	-0.34	-0.56	-2.80
Noncontrolling Interest Sharing Ratio	33.01%	32.48%	30.62%	29.40%	27.87%	27.72%	27.46%	26.91%	27.08%	26.44%	25.15%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.55	2.31	2.30	2.40	2.49	2.30	1.75	1.65	1.60	1.64	1.75
Quick Ratio	2.37	2.15	2.13	2.22	2.30	2.13	1.56	1.47	1.43	1.49	1.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	31	260	218	268	362	518	617	441	260	179	90
Operating Cash Flow to CapEx	3,110.49%	792.76%	6,236.47%	3,424.39%	2,533.51%	74.63%	338.26%	405.76%	687.72%	61.26%	361.15%
Free Cash Flow to Firm to Interest Expense	7.96	66.67	57.25	71.09	96.48	147.50	209.92	147.33	86.64	62.31	34.28
Operating Cash Flow to Interest Expense	2.43	1.21	4.35	3.73	5.18	2.32	8.87	3.11	5.23	0.95	4.40
Operating Cash Flow Less CapEx to Interest Expense	2.36	1.06	4.28	3.62	4.98	-0.79	6.24	2.34	4.47	-0.60	3.18
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.13	0.13	0.15	0.17	0.17	0.19	0.22	0.25	0.26	0.36
Accounts Receivable Turnover	6.56	4.26	4.72	5.83	6.64	4.48	4.98	6.00	6.91	4.59	5.82
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	53.44	56.28	59.80	64.51	61.41	61.05	36.50	34.89	31.54	29.33	20.47
Accounts Payable Turnover	5.65	9.75	10.32	10.44	6.77	6.61	8.70	8.29	6.29	8.11	8.02
Days Sales Outstanding (DSO)	55.62	85.69	77.41	62.63	54.97	81.39	73.30	60.87	52.82	79.50	62.71
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	64.55	37.42	35.36	34.96	53.92	55.18	41.94	44.04	58.01	44.99	45.52
Cash Conversion Cycle (CCC)	-8.93	48.27	42.05	27.67	1.05	26.21	31.37	16.83	-5.18	34.51	17.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,156	1,147	1,153	839	637	560	406	396	371	363	175
Invested Capital Turnover	0.19	0.20	0.20	0.23	0.29	0.30	0.32	0.40	0.48	0.52	0.82
Increase / (Decrease) in Invested Capital	-238	-267	-230	-526	-519	-587	-747	-443	-266	-197	-231
Enterprise Value (EV)	1,198	1,442	1,243	839	654	591	410	511	508	378	158
Market Capitalization	905	1,156	950	644	524	475	326	419	423	296	129
Book Value per Share	$7.62	$7.40	$7.31	$5.47	$4.32	$3.85	$2.86	$2.83	$2.74	$2.72	$1.40
Tangible Book Value per Share	($4.83)	($4.61)	($4.59)	($3.23)	($2.38)	($2.14)	($1.58)	($1.72)	($1.84)	($1.58)	($0.85)
Total Capital	1,463	1,455	1,448	1,136	942	850	607	580	557	544	353
Total Debt	260	256	253	250	246	243	171	169	167	165	163
Total Long-Term Debt	246	243	239	236	233	229	162	160	158	156	154
Net Debt	-47	-52	-42	-47	-59	-47	-30	-15	-19	-16	-15
Capital Expenditures (CapEx)	0.31	0.59	0.27	0.41	0.77	11	7.71	2.29	2.28	4.44	3.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-65	-71	-68	-68	-71	-67	-75	-78	-85	-71	-64
Debt-free Net Working Capital (DFNWC)	242	237	227	229	234	223	126	107	101	110	114
Net Working Capital (NWC)	228	223	214	215	221	209	117	98	92	101	105
Net Nonoperating Expense (NNE)	42	6.31	1.34	47	30	15	26	6.35	12	-1.49	51
Net Nonoperating Obligations (NNO)	-47	-52	-42	-47	-59	-47	-30	-15	-19	-16	-15
Total Depreciation and Amortization (D&A)	17	17	17	17	17	17	18	18	18	18	17
Debt-free, Cash-free Net Working Capital to Revenue	-26.42%	-28.27%	-26.47%	-26.28%	-27.80%	-26.73%	-30.07%	-31.65%	-34.98%	-29.53%	-26.86%
Debt-free Net Working Capital to Revenue	98.34%	94.26%	88.97%	88.44%	91.56%	88.33%	50.87%	43.56%	41.76%	45.37%	47.89%
Net Working Capital to Revenue	92.76%	88.80%	83.59%	83.12%	86.19%	82.87%	47.34%	39.99%	38.15%	41.74%	44.22%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.50)	($0.10)	($0.08)	($1.81)	($1.12)	($0.53)	($0.95)	($0.07)	($0.14)	($0.14)	($1.32)
Adjusted Weighted Average Basic Shares Outstanding	114.53M	112.76M	117.43M	117.75M	116.38M	116.64M	112.78M	106.82M	103.78M	106.65M	104.68M
Adjusted Diluted Earnings per Share	($1.50)	($0.10)	($0.08)	($1.81)	($1.12)	($0.53)	($0.95)	($0.07)	($0.14)	($0.14)	($1.32)
Adjusted Weighted Average Diluted Shares Outstanding	114.53M	112.76M	117.43M	117.75M	116.38M	116.64M	112.78M	106.82M	103.78M	106.65M	104.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	116.33M	117.72M	117.93M	117.12M	115.52M	112.91M	107.34M	104.09M	103.30M	104.47M	105.52M
Normalized Net Operating Profit after Tax (NOPAT)	-3.13	-5.78	-5.40	-2.20	0.55	-68	-4.89	-2.45	-2.37	-4.70	-3.39
Normalized NOPAT Margin	-4.79%	-8.77%	-8.51%	-3.46%	0.88%	-108.70%	-8.27%	-4.03%	-3.94%	-7.64%	-6.05%
Pre Tax Income Margin	-407.53%	-18.48%	-21.26%	-514.75%	-321.46%	-145.47%	-280.41%	-14.50%	-28.76%	-27.95%	-350.07%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-68.20	-3.09	-3.57	-87.18	-53.76	-25.74	-56.15	-2.53	-5.31	-5.52	-73.97
NOPAT to Interest Expense	-53.06	-1.81	-2.98	-68.76	-42.08	-19.86	-44.00	-0.98	-2.03	-6.50	-53.60
EBIT Less CapEx to Interest Expense	-68.28	-3.25	-3.64	-87.28	-53.96	-28.84	-58.77	-3.30	-6.07	-7.07	-75.18
NOPAT Less CapEx to Interest Expense	-53.14	-1.96	-3.05	-68.87	-42.28	-22.97	-46.62	-1.74	-2.79	-8.05	-54.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-6.15%	-4.24%	0.00%	-2.09%	-0.85%	-0.87%	0.00%	-1.20%	-1.93%	-1.58%	0.00%
Augmented Payout Ratio	-6.15%	-4.25%	0.00%	-3.31%	-3.74%	-4.65%	-5.93%	-13.93%	-23.21%	-26.39%	-11.96%

Financials Breakdown Chart

Definitive Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Definitive Healthcare's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Definitive Healthcare's net income appears to be on an upward trend, with a most recent value of -$199.30 million in 2025, falling from $0.00 in 2020. The previous period was -$591.45 million in 2024. Find out what analysts predict for Definitive Healthcare in the coming months.

Definitive Healthcare's total operating income in 2025 was -$224.27 million, based on the following breakdown:

Total Gross Profit: $183.28 million
Total Operating Expenses: $407.55 million

Over the last 5 years, Definitive Healthcare's total revenue changed from $118.32 million in 2020 to $241.52 million in 2025, a change of 104.1%.

Definitive Healthcare's total liabilities were at $356.50 million at the end of 2025, a 26.1% decrease from 2024, and a 35.2% decrease since 2020.

In the past 5 years, Definitive Healthcare's cash and equivalents has ranged from $24.77 million in 2020 to $387.50 million in 2021, and is currently $163.63 million as of their latest financial filing in 2025.

Over the last 5 years, Definitive Healthcare's book value per share changed from -0.01 in 2020 to 2.72 in 2025, a change of -32,495.2%.

Related Companies

Financial statements for NASDAQ:DH last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definitive Healthcare (DH) Financials

Financials Breakdown Chart

Definitive Healthcare Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definitive Healthcare (DH) Financials

Annual Income Statements for Definitive Healthcare

Quarterly Income Statements for Definitive Healthcare

Annual Cash Flow Statements for Definitive Healthcare

Quarterly Cash Flow Statements for Definitive Healthcare

Annual Balance Sheets for Definitive Healthcare

Quarterly Balance Sheets for Definitive Healthcare

Annual Metrics And Ratios for Definitive Healthcare

Quarterly Metrics And Ratios for Definitive Healthcare

Financials Breakdown Chart

Definitive Healthcare Financials - Frequently Asked Questions

When does Definitive Healthcare's financial year end?

How has Definitive Healthcare's net income changed over the last 5 years?

What is Definitive Healthcare's operating income?

How has Definitive Healthcare's revenue changed over the last 5 years?

How much debt does Definitive Healthcare have?

How much cash does Definitive Healthcare have?

How has Definitive Healthcare's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools